ZEALAND PHARMA AS
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1998-01-01
- Employees
- 150
- Market Cap
- $9.1B
Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults
- Conditions
- HypoglycemiaGlucose Metabolism Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Zealand Pharma
- Registration Number
- NCT04824872
A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT04612517
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 85
- Registration Number
- NCT04318743
- Locations
- 🇳🇱
PRA Health Sciences- Location Martini, Groningen, NZ, Netherlands
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT04178447
- Locations
- 🇭🇺
Fázis I-es Klinikai Farmakológiai, Budapest, Hungary
🇭🇺Szent Imre Egyetemi Oktatókórház, Budapest, Hungary
🇵🇱Specjalistyczne Centrum Medyczne - Prywatny Szpital, Kraków, Poland
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT04172441
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
🇩🇪University Children's Hospital, Düsseldorf, Germany
A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
- Conditions
- Healthy
- Interventions
- Drug: Dual GLP-1/GLP-2 Receptor agonists
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 64
- Registration Number
- NCT03994549
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 44
- Registration Number
- NCT03941236
- Locations
- 🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 145
- Registration Number
- NCT03905707
- Locations
- 🇺🇸
University of Chicago Children's Hospital, Chicago, Illinois, United States
🇬🇧St Mark's Hospital, Harrow, United Kingdom
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 92
- Registration Number
- NCT03895697
- Locations
- 🇨🇦
LMC Diabetes & Manna Research, Toronto, Ontario, Canada
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Other: Standard of Care
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 32
- Registration Number
- NCT03777176
- Locations
- 🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States